Jump to Main Content

Clinicians

FDA Approves Romiplostim for Pediatric Patients With ITP

The Food and Drug Administration approved romiplostim (NPLATE, Amgen Inc.) for pediatric patients 1 year of age and older with immune thrombocytopenia for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Citations